Li Yanyi, Zhang Weiting
North China Pharmaceutical Group Corporation Genetech Biotechnology Co. Ltd., Shijiazhuang 050010, Hebei, China.
Sheng Wu Gong Cheng Xue Bao. 2017 Jan 25;33(1):36-43. doi: 10.13345/j.cjb.160241.
IL-6 is an important cytokine that plays an important role in the pathogenesis of rheumatoid arthritis. We summarized the clinical efficacy and safety of tocilizumab, the IL-6 receptor monoclonal antibody in rheumatoid arthritis, and compared tocilizumab with TNF-α blocking mAbs. The efficiency of tocilizuamb is equivalent to that of TNF-α blockers, and each of the drugs has its advantages and disadvantages. We also summarized the clinical trials of the mAbs blocking IL-6 pathway in development. According to the results of recent studies by several research teams including our research group, IL-6 is another key target for the treatment of rheumatoid arthritis after TNF-α. The listing of the IL-6 blockers provides more choices for personalized treatment of rheumatoid arthritis in the future.
白细胞介素-6是一种重要的细胞因子，在类风湿性关节炎的发病机制中起重要作用。我们总结了白细胞介素-6受体单克隆抗体托珠单抗在类风湿性关节炎中的临床疗效和安全性，并将托珠单抗与肿瘤坏死因子-α阻断单克隆抗体进行了比较。托珠单抗的疗效与肿瘤坏死因子-α阻滞剂相当，且每种药物都有其优缺点。我们还总结了正在研发的阻断白细胞介素-6通路的单克隆抗体的临床试验。根据包括我们研究小组在内的几个研究团队最近的研究结果，白细胞介素-6是继肿瘤坏死因子-α之后类风湿性关节炎治疗的另一个关键靶点。白细胞介素-6阻滞剂的上市为未来类风湿性关节炎的个性化治疗提供了更多选择。
